Eshelman School of Pharmacy
ROBERT A. BLOUIN, Dean
Susan J. Blalock (115) Risk Communication, Behavior Change, and Psychosocial Aspects of Chronic Illness
Robert A. Blouin, Effects of Infectious Disease and Trauma on Altered Physiologic States (i.e., Aging and Obesity), and the Expression and Regulation of Drug Metabolizing Enzymes
Kim L. R. Brouwer (62) Hepatobiliary Drug Disposition, Drug Transport, Prediction of Drug Interactions and Hepatotoxicity, Clinical Pharmacokinetics and Quantitative Systems Pharmacology
Moo J. Cho (79) Targeted Drug Delivery
Frederick M. Eckel (9) Exploration and Role Development of Pharmacist as Health Team Member
Stephen Frye, Drug Design, Enzyme Inhibitor Design, Protein Kinases
Leaf Huang (121) Gene Therapy, Targeted Gene/Drug Delivery
Timothy J. Ives, Pharmacotherapy of Chronic Pain and Neuropathic Pain
Bill Janzen, Drug Discovery, High Throughput Screening, Automation, and Process Improvement
Michael Jay (137) Nanotechnology, Nuclear Sciences
Rudolph Juliano, Cell Adhesion Molecules and Signal Transduction, Macromolecular Therapeutics
Angela Kashuba (114) Clinical Pharmacology of Antiretroviral Agents in HIV Treatment, Prediction of Drug-Drug and Drug-Cytokine Interactions and Adverse Effects, Role of Sex and Ethnicity in Drug Disposition.
Harold Kohn (106) Organic, Medicinal, and Bio-Organic Chemistry; Mechanisms of Biochemical and Medicinal Processes; Synthesis and Investigation of Heterocyclic Compounds of Medicinal Interest
David Lawrence (133) Application of Chemical Tools to Biological Questions–Enzyme Sensors; Light-Activated Inhibitors, Sensors, and Signaling Proteins; Light-Induced Gene Expression; Chemical Genomics
Kuo-Hsiung Lee (13) Medicinal Chemistry of Bioactive Natural Products and Synthetic Analogs including Antitumor, Anti-AIDS, Antimalarial, Antihepatic, Anti-inflammatory, Anti-Arthritis, and Antiviral Agents; Antifungal Antibiotics; Insect Antifeedants; Chinese Herbal Medicine
Jian Liu (108) Carbohydrate Biochemistry, Structural and Functional Relationships of Heparan Sulfate
Howard L. McLeod (127) Pharmacogenomics, Translational Pharmacology, Colorectal Cancer
Russell J. Mumper (132) Nanoparticle Engineering for Tumor and Dendritic Cell Targeting Vaccines; Biocompatibility, Hemocompatibility and Toxicology of Nanoparticles and Nanomaterials; Muco-Adhesive Gels and Thin Films for Mucosal Delivery of Drugs, Vaccines and Microbicides’ Anticancer and Anti-inflammatory Properties of Berries and Berry Extracts
J. Herbert Patterson (47) Individualized Pharmacotherapy of Heart Failure
Betsy L. Sleath (91) Provider-Patient Communication about Medications, Health Disparities, Improving Adherence to Medication Regimens
Dhiren R. Thakker (87) Mechanisms of Drug Transport; Pro-Drug Strategies for Enhanced and Targeted Drug Delivery; Disposition of Macromolecules (e.g., Genes)
Alexander Tropsha (81) Molecular Modeling, Computer-Assisted Drug Design, Molecular Dynamics of Proteins, Protein Folding
Paul Watkins, Clinical Pharmacology; Drug-Induced Liver Injury
Xiao Xiao (126) Viral-Based Gene Delivery, Gene Therapy for Muscular Dystrophy and Other Diseases
Kenneth F. Bastow (84) Design and Testing of Antiviral/Anticancer Drugs
Elena Batrakova, Development of Active Targeted Delivery of Therapeutic Polypeptides to the Brain for Treatment of Parkinson’s Disease using Inflammatory-Response Cells as Vehicles
Federico Innocenti, Clinical Pharmacology–Oncology/Pharmacogenomics
Michael B. Jarstfer (112) Chemical Biology to Study Social Behavior and Telomere Biology
Richard J. Kowalsky (26) Application of Radiopharmaceuticals in Nuclear Medicine and Investigational Studies
Andrew Lee (111) Structural Biology, NMR Spectroscopy, Protein Dynamics, Biophysical Dissection of Proteins and Protein-Ligand Interactions
Rihe Liu (113) Proteomics and Functional Genomics
Mary T. Roth-McClurg (125) Medication Management in Primary Care, The Role of Clinical Pharmacist in the Patient-Centered Medical Home, The Quality of Medication Use and Clinical Outcomes in Older Adults
A. Wayne Pittman (30) Hypertension, Clinical Pharmacokinetics, Cardiology and Drug Administration
Ralph H. Raasch (32) Infectious Diseases, Parenteral Nutrition
Jaya Rao (138) Complementary and Alternative Medicine, Patient-Provider Communication, Rode of Diagnostic Testing in Medical Management, Chronic Disease Management
Denise Rhoney, Pharmacotherapy of Acute Neurological Disorders, CSF Pharmacokinetics
Robert Shrewsbury, Basic and Applied Biopharmaceutics and Pharmacokinetics, Patient Care Compounding
Scott Singleton (116) Bio-Organic and Biophysical Chemical Investigations of the Mechanisms DNA Repair, Directed Evolution of Novel Enzymes, Development of Alternate Strategies for Targeting Drug-Resistant Pathogenic Microorganisms
Philip C. Smith (85) Pharmacokinetics, Drug Metabolism
Dennis M. Williams (92) Inhalation Therapy for Pulmonary Disease, Hypertension, Clinical Pharmacokinetics
Timothy J. Wiltshire, Preclinical Pharmacogenetics
William C. Zamboni, Optimization of Chemotherapeutic Treatment of Cancer, Pharmacokinetics, Pharmacodynamics, Pharmacogenetics
Lynn G. Dressler, Policy and Ethical Issues Related to Genomic Medicine and Research with Emphasis on Cancer Pharmacogenomics and Individualized Therapy (Including Health Disparities, Risk Communication, Science Policy and Education/Dissemination for Patients And Providers)
Gang Fang, Evaluation of Treatment Utilization and Outcomes in Populations, Comparative Treatment Effects Research, Patient-Centered Outcomes
Joel Farley (124) Pharmaceutical Policy, Pharmaceutical Outcomes Research, Comparative Effectiveness Research, Medication Adherence
Shawn Hingtgen, Cell-Based Delivery for Treatment of Brain Cancer
Craig R. Lee (128) Cardiovascular Biology, Genomics and Biomarkers, Eicosanoid Metabolism, Inflammation Sam Lai, Infectious Diseases and Lymphatic Drug Delivery
Samuel K. Lai, Mucosal Immunity, Immune-Nanoparticle Interactions and Lymphatic Drug Delivery
Christine Oramasionwu, HIV/AIDS Health Disparities and Health Outcomes, Medication Use in Minority, Underserved, and International Populations Mary Paine, Clinical Pharmacokinetics, Drug Metabolism and Intestinal Transport, Pharmacogenetics
Qisheng Zhang (130) Endogenous Small Molecule-Regulated Cell Signaling and Relevance to Diseases, Phosphoinositide Signaling, Chemistry and Biology of S-adenosylmethionine, Imaging and Regulating Phosphatase PRL-3
Clark D. Jeffries, Chemical Biology and Medicinal Chemistry
Dmitri Kireev, Computational Drug Discovery
Feng Liu, Gene and Drug Delivery
Michael Wagner, Pharmacogenomics, Translational Pharmacology
Research Associate Professors
Jian Jin, Integrative Chemical Biology and Drug Discovery
Juan Li, Gene Therapy
Alexander Golbraikh, Chemical Biology and Medicinal Chemistry, Informatics
Charles Green, Innovative Educational Technologies
Susan Morris-Natschke (102) Design, Synthesis and Structural Optimization of Antiviral Phospholipids
Research Assistant Professors
James Auman, Pharmacogenomics and Individualized Therapy
Rahima Benhabbour, Organic Chemistry and Drug Delivery
Delesha Carpenter, Medication Adherence, Chronic Disease Self-Management
Anthony Di Pasqua, Bioorganic Chemistry and Tumor Biology
Julie Dumond, Pharmacometrics, Clinical Pharmacokinetics
Ruth Everett, Metformin Intestinal Absorption, Transport Mechanisms and Anticancer Activities, Modulation of Tight Junctions for Enhanced Drug Delivery
John R. Kagel, Bioanalysis, GLP
Keduo Qian, Chemical Biology and Medicinal Chemistry
Chunping Qiao, Gene Therapy
Mary Roederer, Medical Decision-Making Integrating Pharmacogenomics/Pharmacogenetics Data at the Individual Patient Level and Formulary Level, Education of Pharmacists and Pharmacy Students Regarding Pharmacogenomics/Pharmacogenetics
Vyas Sharma, Chemical Biology and Medicinal Chemistry
Ruhang Tang, Molecular Pharmaceutics
Qunzhao Wang, Biochemistry
Xiang Wang, Molecular Modeling
Xiaodong Wang, Therapeutic Targets in Oncology
Zhuo Wang, Drug Metabolism and Pharmacokinetics
Kristina Wolf, Intestinal Metabolism and Transporter-Based Drug Interactions
Wei Yue, Regulation of Hepatic Uptake Transporters
Hao Zhu, Molecular Modeling
J. Heyward Hull, Cardiovascular Pharmacology, Clinical Pharmacokinetics, Study Design and Analysis
Greene Shepherd, Clinical Toxicology
K.T. L. Vaughn, Pharmacy Practice and Experiential Education, Clinical Library Sciences
Clinical Associate Professors
Betsy Bryant Shilliday, Pharmacy Practice and Experiential Education, Pharmacotherapy of Anticoagulation, Health Literacy, Transitions of Care, Quality Improvement, Patient Outcomes Research
Amanda H. Corbett, Pharmacology of Antiretrovirals, Opportunistic Infection Therapies in Resource-Poor Countries
Stephen Dedrick, Continuing Professional Education
Betty Dennis, Pharmacy Practice and Experiential Education
Robert E. Dupuis, Clinical Pharmacokinetics, Drug Metabolism of Immunosuppressants in Organ Transplant Recipients, Relationship between Drug Metabolism, Toxicity and Outcomes
Stefanie P. Ferreri, Evaluating Pharmaceutical Care in the Community Pharmacy Setting
John Kessler, Medication Safety
Macary Marciniak, Evaluating Pharmaceutical Care in the Community Pharmacy Setting
Robb Malone, Pharmacy Practice and Experiential Education
Elizabeth Michalets, Pharmacy Practice and Experiential Education
Adam M. Persky, Pharmacy Education, Pharmacokinetics and Pharmacodynamics of Dietary Supplements
Jo Ellen Rodgers, Clinical and Translational Research in Heart Failure
Phillip T. Rodgers, Experiential Education Methods and Outcomes
Mollie A. Scott, Pharmacy Practice and Experiential Education, Patient Centered Medical Homes Models of Pharmacy Practice, Osteoporosis, Billing for Cognitive Services, Interprofessional Education
Clinical Assistant Professors
Heidi Noel Anksorus, Pharmacy Practice and Experiential Education, Patient Care Laboratory, Acute Care Pharmacotherapy
Jena Ivey Burkhart, Innovative Practice Models in Geriatrics, Geriatric Interdisciplinary Training among Healthcare Professional Students, Clinical Pharmacist Interventions in the Primary Care Setting
Paul Bush, Pharmacy Practice and Experiential Education, Expansion of Pharmacists’ Role in the Delivery of Patient Care
Kristen Bova Campbell, Pharmacy Practice and Experiential Education
Wendy Cox, Professional Education
Rowell Daniels, Pharmacy Practice and Experiential Education, Expansion of Pharmacists’ Role in the Delivery of Patient Care
Lisa Dinkins, Pharmaceutical Care Labs, Evaluating Pharmaceutical Care in the Community Pharmacy Setting
Stephen Eckel, Pharmacy Practice and Experiential Education, Utilization of Pharmacy Automation, Role of Pharmacists in Improving Patient Care
Robert Granko, Pharmacy Practice and Experiential Education, Expansion of Pharmacists’ Role in the Delivery of Patient Care
Roy Hawke (118) Clinical Pharmacology of Natural Products and Their Mechanisms of Action and Disposition in Liver Disease
Bill Hitch, Pharmacy Practice and Experiential Education
Debra Kemp, Pharmacy Practice, Ambulatory Care Pharmacotherapy Evaluation
Ruth Ann Lee, Innovative Ambulatory Care Practice Model in Solid Organ Transplant
Barbara Kostic, Pharmacy Practice and Experiential Education
Kim Leadon, Professional Experience
Adam Orsborn, Pharmacy Practice and Experiential Education, Improving Efficiency in Workflow Systems
Tracie Rothrock-Christian, Pharmacy Practice and Experiential Education
Scott W. Savage, Pharmacy Practice and Experiential Education, Expansion of Pharmacists’ Role in the Delivery of Patient Care
Kelly Scolaro, Patient Care Labs, Geriatric Pharmacotherapy
John M. Valgus, Pharmacy Practice and Experiential Education
Christine M. Walko, Clinical Pharmacology of Anticancer Drugs, Clinical Pharmacokinetics of Anticancer Drugs, Cancer Pharmacogenomics
Latasha Weeks, Health Disparities, Rural and Minority Health, Cultural Competency, Health Literacy
Carla White, Educational Policy and Philosophy, Communication Theory, and Strategic Program and Leadership Development
Patricia J. Bush
Michael Crimmins, New Methodology and Synthesis of Natural Products
Joseph DeSimone, Polymer Synthesis, Liquid and Supercritical CO2 Processing, Gene Therapy and Drug Delivery
Klaus Hahn, Tools for Studying Signaling Dynamics
Lawrence Lesko, Clinical Pharmacology and Drug Development
Wenbin Lin, Crystal Engineering
Elaine Mardis, Characterization of Cancer Genomes, Genome Sequencing Technologies
Gerald Miwa, Drug Metabolism and Drug Development
Gary Pollack, Pharmacokinetics, Pharmacodynamics
John Robert Powell, Clinical Pharmacology and Drug Development
Jack Reynolds, Toxicity and Drug Development
Bryan Roth, GPCR Structure
Robert Voyksner, Mass Spectrometry
Daryl C. Zeldin, Respiratory Biology, Exposure Assessment and Prevention of Asthma, Eicosanoid Metabolism
Adjunct Associate Professors
Andrea K. Biddle
David M. Cocchetto, Clinical Pharmacology, Antiviral/Antibacterial Regulatory Affairs
Paul A. Dayton, Biomedical Engineering and Ultrasound
Patricia Deverka, Medical Technology Policy
Felix Frueh, Pharmacogenomics and Clinical Pharmacology
Alan Higgins, Preclinical Drug Development
Nancy Allen Lapointe, Translational Research of Antiarrythmic Drug Therapy
Steven R. Moore
Michael Murphy, Molecular Genetics
William T. Sawyer, Drug Development
Dan Weiner, Pharmacometrics, Pharmaceutical Biostatistics
Issam Zineh, Pharmacogenomics and Clinical Pharmacology
Zhiyang Zhao, Pharmacokinetics and Drug Metabolism
Adjunct Assistant Professors
Peter Bonate, Pharmacokinetics Modeling Simulation
Jack W. Campbell
Eric Faulkner, Personalized Medicine Development
Mona Fiuzat, Heart Failure Drug Development and Pharmacogenomics
Alex Zhenghong Fu
Giulia Ghibellini, Pharmacokinetics, Clinical Pharmacology
Allison Harrill, Toxicology, Drug-induced Liver Injury
Phil Mendys, Cardiovascular Drug Development and Preventive Cardiology
Alison A. Motsinger, Pharmacogenetics, Bioinformatics
Kouros Owzar, Biostatistics and Bioinformatics
Nita Patel, Preclinical Drug Development
Erick Peters, Psychiatric and Cancer Pharmacogenomics
Cosette Serabjit-Singh, Computational Approaches to Predicting ADME Parameters/Pharmacogenetics
Russell Thomas, Genomic Biology and Bioinformatics
Andrew Z. Wang, Radiation Oncology, Nanomedicine
Maceij Zamek-Gliszczynski, Preclinical Drug Development
George H. Cocolas
Khalid S. Ishaq
Tom S. Miya
G. Joseph Norwood
The UNC Eshelman School of Pharmacy offers graduate curricula leading to the master of science in health-system pharmacy and doctor of philosophy in pharmaceutical sciences. Graduate study may be concentrated in disciplinary areas represented by the divisions of chemical biology and medicinal chemistry, molecular pharmaceutics, pharmaceutical outcomes and policy, pharmacotherapy and experimental therapeutics, and pharmacy practice and experiential education.
Instruction emphasizes contemporary research methods and results and is given by means of lectures, recitations, and seminars combined with intensive laboratory-based research. The excellent rapport that exists between schools, departments, institutes, and centers within the University facilitates interdisciplinary collaborative research by graduate students and faculty. The graduate degree programs also benefit from faculty affiliations with GlaxoSmithKline, Inc., the Research Triangle Institute, Duke University, the Wake Forest University School of Medicine, and many other organizations in the Research Triangle Park area. The UNC Eshelman School of Pharmacy occupies Beard and Kerr Halls, which are located on the health sciences campus together with the Schools of Dentistry, Medicine, and Nursing and the Gillings School of Global Public Health. The Health Sciences Library has an outstanding collection of books and journals as well as computer and support services. Library and laboratory resources residing in other University departments are also available for use by students and faculty.
The School offers a Ph.D. in pharmaceutical sciences with a concentration in one of four areas: chemical biology and medicinal chemistry, molecular pharmaceutics, pharmacotherapy and experimental therapeutics, or pharmaceutical outcomes and policy.
Chemical Biology and Medicinal Chemistry
Chemical biology and medicinal chemistry are multidisciplinary fields that integrate organic chemistry, biochemistry, molecular biology, structural biology, pharmacology, and physiology. The research in the division applies and extends the basic concepts of chemistry, biochemistry, and pharmacology to the investigation of biomedical problems. General areas of study include structure-activity relationships, drug-receptor interactions, synthetic drug design, and target discovery and validation. Specific focus areas include cancer chemotherapy, computer-aided drug design, enzymology, glycobiology, molecular modeling, natural products, neurochemistry, parasitology, and structural biology.
A Ph.D. is offered with a concentration in chemical biology and medicinal chemistry.
Molecular pharmaceutics represents interdisciplinary specialties encompassing a range of scientific endeavors, including: 1) the design, fabrication, evaluation, use of, and delivery strategies for dosage forms, 2) elucidation of the behavior of pharmacologic agents in biologic systems, 3) determination of the ability of pharmacologic agents to reach the relevant site of biologic effect and 4) determination of the time course of biologic activity. These areas of specialization represent critical steps in the development of new therapeutic agents, the evaluation of new and existing drugs, and the optimal clinical use of pharmacologic agents.
Students in the Division of Molecular Pharmaceutics are required to participate in a common core of entry-level graduate courses. This core provides a broad perspective of the pharmaceutical sciences as well as an appreciation for how different subdisciplines interact. Many dissertation projects are collaborative in nature and rely upon interactions with faculty in other divisions of the UNC Eshelman School of Pharmacy, as well as with colleagues in the School of Medicine, the Department of Chemistry, or at pharmaceutical companies or institutions located in the Research Triangle Park area.
A Ph.D. is offered with a concentration in molecular pharmaceutics.
Pharmaceutical Outcomes and Policy
The Division of Pharmaceutical Outcomes and Policy offers a Ph.D. program in pharmaceutical sciences emphasizing an interdisciplinary approach to addressing issues relevant to medication use at the patient, provider, community, and societal levels. Faculty research interests and course offerings reflect this interdisciplinary orientation. Students develop knowledge and skills that enable them to conduct high quality research directed at improving the use and cost effectiveness of medications, technology and services. Education and research in the division draws heavily upon expertise in numerous fields such as: health services research, health policy, health communication, health behavior and behavior change, epidemiology, and psychometrics. Areas of faculty and student research include: communication and decision making, comparative effectiveness of medications and pharmacy practice models, medication adherence and self-management, health disparities, health literacy, patient reported outcomes assessment, pharmaceutical policy analysis, and policy and ethical issues related to pharmacogenomics.
A Ph.D. is offered with a concentration in pharmaceutical outcomes and policy.
Pharmacotherapy and Experimental Therapeutics
The Division of Pharmacotherapy and Experimental Therapeutics offers a Ph.D. program in the pharmaceutical sciences with a focus on translational research, clinical pharmacology, and experimental therapeutics. The goal of the program is to develop clinician scientists who are prepared to generate, integrate and disseminate new knowledge to optimize drug therapy and improve health outcomes for the benefit of patients and society. Graduate students engage in clinical experiences throughout the program that are designed to complement each student’s research interests while also facilitating their development as translational scientists. Areas of graduate coursework and research include drug metabolism and transport, pharmacokinetics/pharmacodynamics/pharmacometrics, pharmacogenomics, clinical research, drug development, experimental therapeutics, and mechanisms of drug toxicity. Therapeutic and research areas of particular strength include cardiovascular disease, infectious disease/HIV, oncology/hematology, hepatology/gastroenterology/transplant, and pulmonary disease.
A Ph.D. is offered with a concentration in pharmacotherapy and experimental therapeutics.
Requirements for Admission to the Ph.D. Program
Applicants who have completed a standard collegiate curriculum in pharmacy, chemistry, biochemistry, biology, engineering, or in an allied field in the University, or in other universities or colleges having curricula acceptable to the UNC–Chapel Hill Graduate School, are eligible for admission to the graduate program in pharmaceutical sciences. Applications for admission must be supported by scores on the Graduate Record Examination, letters of recommendation, official transcripts, and a statement of personal goals as they relate to graduate study at the UNC Eshelman School of Pharmacy.
The Graduate School online application (gradschool.unc.edu/admissions) is the standard means of applying for admission. Inquiries concerning admission to programs in the pharmaceutical sciences may be directed to the Office of Research and Graduate Education, CB# 7567, 29 Beard Hall, Chapel Hill, NC 27599-7567.
Master of Science in Health-System Pharmacy
The Division of Pharmacy Practice and Experiential Education offers the master of science in health system pharmacy with a goal of preparing pharmacists for leadership positions in health care. In order to accomplish this goal, the program will provide students with the knowledge, skills and experience necessary to assume a variety of roles and responsibilities. Our graduates will serve as vibrant, committed professionals with a focus on improving patients’ health, health-care delivery, and the profession of pharmacy. This will occur through both didactic education and experiential opportunities in class and in the workplace.
Graduate Assistantships and Fellowships in the UNC Eshelman School of Pharmacy
Graduate teaching and research assistantships in the UNC Eshelman School of Pharmacy provide a stipend of $25,500 for 12 months’ service. All awards are made on a competitive basis with consideration given to the applicant’s academic record and Graduate Record Examination scores. Information concerning these assistantships, fellowships, and traineeships may be obtained by writing directly to the Office of Research and Graduate Education at the UNC Eshelman School of Pharmacy.
Courses for Graduate Students
804 Drug Discovery Targets I (3). Prerequisites, CHEM 261 and 262. Introduction to the principles of design and discovery of effective therapeutic agents. Concepts of physical chemistry, pharmacokinetics and disposition, and analytical techniques in the context of drug design.
805 Molecular Modeling (BIOC 805) (3). See BIOC 805 for description.
806 Macromolecular Modeling (BIOC 806) (3). Prerequisites, MATH 231, 232, and CHEM 430. Introduction to modeling and simulation techniques for biological macromolecules. Two lecture and three to four laboratory hours per week.
807 Foundations of Chemical Biology I: Organic and Medicinal Chemistry (3). Prerequisite, CHEM 262. The elements of organic chemistry required for the design and synthesis of chemical probes and biologically active compounds.
821 Chemistry of Natural Products (3). Prerequisite, CHEM 466. Permission of the instructor. An introduction to the isolation, structure determination, biosynthesis, and synthesis of bioactive natural products; emphasis on aspects relating to medicinal chemistry. Three hours a week.
822 Selected Topics in Natural Products (2). Prerequisites, CHEM 466 and 468. Discussions of important recent developments in the chemistry of natural products of biomedical significance.
833 Molecular Target-Based Drug Discovery (3). Prerequisite, MEDC 804. An integrated introduction to molecular target-based drug discovery including bioactive natural products, neuropharmacology, chemical biology, and recent advances and techniques in drug discovery.
836 Selected Topics in Synthetic Medicinal Chemistry (2). Prerequisite, CHEM 460. Discussions from current literature on the strategy and techniques involved in the synthesis of drug molecules. Two lecture hours a week.
842 Therapeutic Proteins (3). This course covers applications of modern information theory and information technologies to biomolecular systems. The core of this course is an overview and practical applications of methods and techniques for the analysis of nucleic acid and protein sequences, sequence-structure, and sequence-function correlations.
899 Seminar (1). Seminar consists of presentations on current research topics by the division’s graduate students, faculty and invited speakers from industry, government, and other academic departments and institutions. Only four credits of MEDC 899 may count toward requirement for the PhD degree (two credits for MS).
900 Introduction to Research in Medicinal Chemistry (1–3). Prerequisites, CHEM 261 and 262. Permission of the instructor. One conference and three or more laboratory hours a week.
991 Research in Medicinal Chemistry (1–9). One conference and nine laboratory hours a week per course.
993 Master’s Thesis (3). After didactic course work is complete, master’s students register for three credits of MEDC 993 during the fall and spring semesters.
994 Doctoral Dissertation (3). Students register for dissertation credits after successfully completing all didactic course work. A minimum of six credit hours are required for graduation.
Courses for Graduate Students
738 Nanomedicine (3). Offers an introduction to the interdisciplinary field of nanomedicine for students with physical, chemical, or biological sciences background. It will emphasize emerging nanotechnologies and biomedical application.
801 Nuclear Pharmacy 1 (3). Prerequisite, PHCY 411. Permission of the instructor. Basic principles of radiation physics, instrumentation, radiation safety, and radiation biology.
802 Nuclear Pharmacy 2 (3). Prerequisite, MOPH 801. Permission of the instructor. Chemical principles underlying the preparation, regulatory control, and use of radioactive drugs in nuclear medicine.
810 Drug Metabolism (3). Permission of the instructor. Introduction to the use of concepts, chemistry, enzymology, and techniques in drug metabolism for the design and development of safe and effective therapeutic agents.
840 Introduction to Research (1–3). Permission of the instructor. Students participate in research projects designed to introduce them to research opportunities in the pharmaceutical sciences.
850 Pharmaceutical Analysis (1). Permission of the instructor. Introduction to quantitative instrumental analysis in pharmaceutics. One lecture hour a week.
862 Advanced Pharmaceutics (3). Discuss industrial approaches to pharmaceutical formulation development.
864 Advances in Drug Delivery (4). Prerequisites, PHCY 410 and 411. Permission of the instructor for students lacking the prerequisites.
865 Trends in Molecular Pharmaceutics Research (3). Prerequisite, MOPH 864. An interactive course in which students actively participate by critical evaluation and discussion of current literature in the field of drug delivery.
890 Special Topics in Advanced Pharmaceutics (1–12). Permission of the instructor. A lecture and/or laboratory course designed to present new concepts and innovations in the area of drug delivery and disposition.
899 Seminar (1). Seminar consists of presentations on current research topics by the division’s graduate students, faculty and invited speakers from industry, government, and other academic departments and institutions. Only four credits of MOPH 899 may count toward requirement for the PhD degree (two credits for MS).
900 Introduction to Research in MOPH (2–3). This course provides students the opportunity to work with a faculty mentor on a research project.
991 Research (1–12). Graduate course consisting of laboratory-based research, conferences with the major professor, and library investigations relating to research. One conference and nine laboratory hours a week per course.
993 Master’s Thesis (3). After didactic course work is complete, master’s students register for three credits of MOPH 993 during the fall and spring semesters.
994 Doctoral Dissertation (3). Students register for dissertation credits after successfully completing all didactic course work. A minimum of six credit hours are required for graduation.
Pharmaceutical Outcomes and Policy
Courses for Graduate Students
801 Economics and Behavior of the International Pharmaceutical Industry (HPM 653) (3). This course focuses on the empirical investigation of the economic and health impact of major pharmaceutical policies, regulations, market conditions, prescription drug use, and pharmaceutical care.
803 Social and Behavioral Aspects of Pharmaceutical Use (3). This course will draw upon medical sociology and health psychology to familiarize students with core theories, research, measures and design issues relevant to conducting social/behavioral research in pharmaceutical use.
804 Informatics: Use of Large Health Care Databases (3). Interdisciplinary course providing practical training in the analysis of large, secondary databases containing physician, hospital, and pharmaceutical data. Course topics include data preparation, algorithm development, quality control, and dataset limitations.
805 Patient-Reported Outcomes: Theory, Methods, and Applications (3). Course examines theoretical and methodological issues related to the assessment of patient reported outcomes, including health-related quality-of-life, in pharmaceutical research. Current and potential applications are highlighted.
806 Pharmaceutical Policy (3). Course examines policies that influence pharmacy. Structured methods of policy analysis are examined and used to assess theoretic and analytic applications for evaluating pharmaceutical policy.
872 Proposal Writing in DPOP (3). How to write research proposals, including dissertation grants.
899 Seminar (1). Forum for scholarly discussion of policy issues, research ideas and methods, campus and industry research resources, and the presentation of ongoing research. In addition to presentations by DPOP faculty and students, seminar will include presentations from invited researchers from industry, managed care, foundations, health care organizations, clinicians, and other departments.
900 Introduction to Research in DPOP (2–3). This course offers students the opportunity to work with a faculty mentor on a research project.
901 Selected Topics in Pharmaceutical Outcomes and Policy (1–3). A reading and/or special projects course for both undergraduate and graduate students interested in pursuing additional work in the administrative and social sciences as they pertain to pharmacy practice. One to three hours a week.
902 Methods in Pharmaceutical Outcomes Research (3). Includes formulating a research question, stating aims and hypothesis. Students are introduced to formulating a research strategy to write the background of the protocol, developing a research methodology, addressing measurement issues, selecting an appropriate design, and performing statistical analysis and power calculations. Three lecture hours a week.
991 Research in Pharmaceutical Outcomes and Policy (1–6). Consists of laboratory work, conferences with the major professor and library investigations relating to research.
993 Master’s Thesis (3). A minimum of six hours of thesis credit must be taken in order to complete the requirements for the master’s degree.
994 Doctoral Dissertation (3). There is no limit to the number of dissertation hours that can be taken; however, no more than six hours may be applied to the minimum of 45 hours needed to satisfy graduation requirements.
Pharmacotherapy and Experimental Therapeutics
Courses for Graduate Students
809 Hubbard Program (3). This interdisciplinary course for health professions students trains students to practice collaboratively in the care of their older patients.
813 Cardiovascular Pharmacy (3). Provides an in-depth discussion of the pharmacotherapy of major cardiovascular diseases such as hypolipidemia, hypertension, ischemic heart disease, heart failure, and arrhythmias.
815 Interdisciplinary Teamwork in Geriatrics (3). Course emphasizes the acquisition of skills and competencies necessary to provide effective interdisciplinary geriatrics care and leadership in a variety of settings, including rural and/or underserved communities.
816 Integrative Medicine (2). This is a survey course intended to introduce students to various complementary and alternative medicine practices, and their integration into traditional medicine. It will utilize active learning strategies to enhance student involvement.
818 Foundations in Exercise Prescription (2). This course is designed to introduce basic concepts and selected therapeutic applications of exercise testing and prescription.
821 Principles of Pharmacy Practice (3). Prerequisite, PHPR 249. Students discuss the modern role of the hospital pharmacist and how the role integrates progressive management with innovative services. The problems with implementing these programs are evaluated. Three lecture hours a week.
822 Advanced Clinical Pharmacy (3). Discussions, workshops, and lectures to develop the student’s skills and abilities to make therapeutic recommendations, utilize drug literature, educate patients and health professionals, and record observations, plans, and actions in a problem-oriented record.
830 Clinical Investigation of Drugs (2). Includes preclinical drug safety evaluation, preclinical pharmacology, design of protocols for Phases I–IV, FDA guidelines for clinical study, preparation of study plan, statistics in clinical trials, data analyzing, and FDA interactions with industry.
831 Quantitative Methods in Clinical Research (3). Required preparation, introductory biostatistics or general statistics. Graduate standing or permission of the instructor. This course reviews statistical concepts and discusses the most commonly used statistical methods for analysis of data from clinical studies or research experiments. Students will analyze problem datasets using SAS.
833 Experimental Design Considerations in Clinical Research (2). Course provides an overview of clinical trials methodology, focusing primarily on designs of (and common flaws in) clinical drug trials and nonclinical research experiments intended to answer clinical questions.
834 Methods in Quantitative Systems Pharmacology (3). Prerequisites, DPET 855 and 856. Open to graduate and PY3 students. This course utilizes hands on experiences to introduce the student to the principles and practices of contemporary quantitative systems pharmacology.
836 Elements of Scientific Writing and Communication (2). This course is designed to help students develop strategies for presenting research ideas and results in written and oral form and for participating effectively in the peer review process.
838 Methods in Pharmacogenomics (2). Prerequisite, DPET 832. Permission of the instructor for students lacking the prerequisite. The goals of this course are to provide graduate students with an understanding of major genomic discovery methodologies and their application for solving translational research problems.
840 Advanced Pharmacotherapy (3). A modular approach to advanced level pharmacotherapy. Coursework using the Pharmacotherapy Self Assessment Program (PSAP) aimed at improving clinical skills and reviewing standards of practice.
841 Science and Methods in Drug Development (2). Provides working knowledge of commonly-used processes, techniques, and methods involved in drug development processes, emphasizing pre-clinical aspects. Lectures and in-class case-based interactive discussion. Students will develop problem-solving skills, writing and presentation skills, and will be exposed to analytical and pharmaceutical methods and gain experience interpreting data for regulatory approval.
855 Principles of Pharmacokinetics (3). Prerequisite, PHCY 413. Permission of the instructor. Introduction to pharmacokinetic theory, mathematical model development, and data analysis techniques.
856 Advanced Pharmacokinetics and Pharmacodynamics (4). Prerequisite, MOPH 855. Permission of the instructor. Advanced treatment of contemporary pharmacokinetic theory and application, with emphasis on model development, analytical approaches to parameter estimation, and experimental design/data analysis.
899 Seminar (1). This seminar series consists of presentations on current research topics by the Division’s graduate students and faculty, and for the presentation of ‘Journal Club’ articles by graduate students and post-doctoral fellows. Seminar also includes invited speakers from industry, government, and other academic departments and institutions.
900 Research in Pharmacy Practice (1–5). Consists of conferences with major professor; library, laboratory, and/or field investigations relating to research. Professor in charge is responsible for the assignments and approval of the subject and character of the degree paper.
991 Research in Experimental Therapeutics (3). No later than second semester in residence, graduate students must register for mentored research experience which is graded H, P, L, or F in accordance with customary Graduate School procedures. To receive full credit, research reports must be filed with the DDGS at the end of each semester.
993 Master’s Thesis (3). After didactic course work is complete, master’s students register for three credits of DPET 993 during the fall and spring semesters.
994 Doctoral Dissertation (3). Students register for dissertation credits after successfully passing the preliminary doctoral written and oral examinations. A minimum of six credit hours for dissertation research and writing is required for graduation. Students must register for at least three credit hours in the semester in which the final defense is conducted.
Pharmaceutical Sciences (Interdisciplinary)
Courses for Graduate Students
800 Applied Pharmaceutical Statistics (3). Application of statistical analysis concepts and tools including probability, statistical inference, and regression analysis. Experimental design and statistical modeling approaches appropriate to common pharmaceutical research scenarios.
801 Ethics in Research (1). Overview of the research process, including hypothesis testing, scientific writing, construction of research proposals, and research ethics.
805 Independent Study and Research in Pharmacy (1–6). Required preparation, arranged with the faculty member in each individual case. Contract with a faculty member required. Permission of the instructor. Provides opportunities for professional (doctor of pharmacy) students to conduct independent study or participate in research projects designed to introduce them to a specialized area of practice or research.
806 Contemporary Topics in Pharmacy (1–3). Experimental course, for professional (doctor of pharmacy) students, to determine the need and demand of courses in new content areas. Topics will be chosen by faculty based on current issues.